日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Sigma-2 receptor modulator CT1812 alters key pathways and rescues retinal pigment epithelium (RPE) functional deficits associated with dry age-related macular degeneration (AMD)

Sigma-2 受体调节剂 CT1812 改变关键通路并挽救与干性年龄相关性黄斑变性 (AMD) 相关的视网膜色素上皮 (RPE) 功能缺陷

Britney N Lizama #, Eloise Keeling #, Eunah Cho, Evi M Malagise, Nicole Knezovich, Lora Waybright, Emily Watto, Gary Look, Valentina Di Caro, Anthony O Caggiano, J Arjuna Ratnayaka, Mary E Hamby

Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification

CT1812 的临床前和临床生物标志物研究:阿尔茨海默病治疗的新方法

Nicholas J Izzo, Carla M Yuede, Kelsie M LaBarbera, Colleen S Limegrover, Courtney Rehak, Raymond Yurko, Lora Waybright, Gary Look, Gilbert Rishton, Hank Safferstein, Mary E Hamby, Claire Williams, Kelsey Sadlek, Hannah M Edwards, Charles S Davis, Michael Grundman, Lon S Schneider, Steven T DeKosky,

Sigma-2 receptor antagonists rescue neuronal dysfunction induced by Parkinson's patient brain-derived α-synuclein

Sigma-2 受体拮抗剂挽救帕金森病患者脑源性 α-突触核蛋白引起的神经元功能障碍

Colleen S Limegrover, Raymond Yurko, Nicholas J Izzo, Kelsie M LaBarbera, Courtney Rehak, Gary Look, Gilbert Rishton, Hank Safferstein, Susan M Catalano

Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits

针对淀粉样蛋白 β 1-42 寡聚体的阿尔茨海默病治疗 I:Abeta 42 寡聚体与特定神经元受体的结合被改善认知缺陷的候选药物所取代

Nicholas J Izzo, Agnes Staniszewski, Lillian To, Mauro Fa, Andrew F Teich, Faisal Saeed, Harrison Wostein, Thomas Walko 3rd, Anisha Vaswani, Meghan Wardius, Zanobia Syed, Jessica Ravenscroft, Kelsie Mozzoni, Colleen Silky, Courtney Rehak, Raymond Yurko, Patricia Finn, Gary Look, Gilbert Rishton, Han